In the management of acute deep vein thrombosis, which drug is not suitable as a sole therapy?

Study for the Foundation Year Pharmacy – Clinical Practice Test. Prepare with detailed questions, step-by-step explanations, and test format insights. Enhance your readiness and confidence!

Multiple Choice

In the management of acute deep vein thrombosis, which drug is not suitable as a sole therapy?

Explanation:
Treating acute DVT requires effective anticoagulation to prevent clot growth and pulmonary embolism. Antiplatelet drugs like clopidogrel target platelets and are most beneficial for arterial clots, where platelet aggregation drives the process. Venous clots, by contrast, are driven more by the coagulation cascade and fibrin formation, so anticoagulants are needed to interrupt that process. Enoxaparin, rivaroxaban, and apixaban are anticoagulants used as single-agent therapy for DVT, providing reliable anticoagulation from the start. Clopidogrel does not provide adequate anticoagulation for venous thromboembolism when used alone, so it is not suitable as sole therapy for acute DVT.

Treating acute DVT requires effective anticoagulation to prevent clot growth and pulmonary embolism. Antiplatelet drugs like clopidogrel target platelets and are most beneficial for arterial clots, where platelet aggregation drives the process. Venous clots, by contrast, are driven more by the coagulation cascade and fibrin formation, so anticoagulants are needed to interrupt that process. Enoxaparin, rivaroxaban, and apixaban are anticoagulants used as single-agent therapy for DVT, providing reliable anticoagulation from the start. Clopidogrel does not provide adequate anticoagulation for venous thromboembolism when used alone, so it is not suitable as sole therapy for acute DVT.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy